1-20 of 1246 Search Results for

company

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
×Close Modal
Sort by
Journal Article
Journal of Health Politics, Policy and Law (1 June 2013) 38 (3): 505–544.
Published: 01 June 2013
...Denis G. Arnold; James L. Oakley As the pharmaceutical industry lobbies European regulators to permit direct-to-consumer advertising (DTCA) of prescription drugs in the European Union, we found that five leading companies violated industry-developed and -promulgated standards for ethical...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2002) 27 (1): 5–30.
Published: 01 February 2002
... insurance. In an extensive survey of health care purchasing practices among Fortune 500 companies we found that major companies are not using the managed competition approach to health care purchasing. Instead, most of the companies surveyed are purchasing health care in the same way as they do other inputs...
Journal Article
Journal of Health Politics, Policy and Law (1 February 1987) 12 (1): 53–76.
Published: 01 February 1987
... and format, minimum rates of return, sale of these policies related to disclosure requirements, consumer information activities, and penalties for agent and company abuse. This paper examines the impact of specific regulations on the ratio of the expected policy benefits per premium dollars and on the...
Journal Article
Journal of Health Politics, Policy and Law (1 February 1982) 7 (1): 80–95.
Published: 01 February 1982
... is a large, stable segment of the prepaid industry that developed as a result of private sector and community concern long before the federal HMO Act of 1973, and it is their initiatives along with increasing investment activity by insurance companies and management companies in particular, that will...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2008) 33 (5): 943–963.
Published: 01 October 2008
...Christy A. Rentmeester; Robert I. Garis How ought we determine whether businesses in the health care sector profit fairly? One class of companies in the health care sector, pharmacy benefit managers (PBMs), deserves special consideration. We describe two specific revenue-generating practices...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2006) 31 (3): 497–510.
Published: 01 June 2006
... collectively with insurance companies, as a means of counteracting insurers' monopsony power. It is not clear that health insurers possess significant monopsony power. Even if they do, bestowing monopoly power on physicians will not necessarily improve matters. Active antitrust enforcement in insurance markets...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2016) 41 (1): 101–116.
Published: 01 February 2016
... exchanges through which middle-income individuals can purchase coverage from private insurance companies. However, while the ACA provisions exclude all undocumented and some documented immigrants, Massachusetts uses state and hospital funds to extend coverage to these groups. This article examines the ACA...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1992) 17 (2): 329–352.
Published: 01 April 1992
... social accommodation rather than health. To succeed, Philip Morris's effort had to be widely accepted and noncontroversial. Proponents of the ordinance countered with controversy to undermine the campaign and expose the company's intentions. The controversy made the established health organizations...
Journal Article
Journal of Health Politics, Policy and Law (1 June 2011) 36 (3): 547.
Published: 01 June 2011
... The Patient Protection and Affordable Care Act (ACA) of 2010 clearly builds on the existing health care system in the United States. By creating health insurance exchanges, the ACA attempts to extend the use of private insurance companies to expand coverage. It also attempts to improve existing...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2012) 37 (5): 741–778.
Published: 01 October 2012
...Anne-Laure Beaussier The 2010 Patient Protection and Affordable Care Act was a major legislative achievement of the 111th Congress. This law structurally reforms the US health care system by encouraging universal health care coverage through regulated competition among private insurance companies...
Journal Article
Journal of Health Politics, Policy and Law (1 June 1986) 11 (3): 525–535.
Published: 01 June 1986
...Stephen Shmanske; Tina Stevens In this paper we present the results of an empirical study of Arizona's medical malpractice review panels. We compare insurance company claim files data from before and after the implementation of panels to analyze the effects of the panel system. The data indicate...
Journal Article
Journal of Health Politics, Policy and Law (1 October 2016) 41 (5): 969–995.
Published: 01 October 2016
..., to exploit the agreements, and associated veto points, through which they are most likely to succeed in blocking or deterring new regulation. These concepts are illustrated with reference to two case studies of investor–state disputes involving a transnational tobacco company, but the implications of...
Journal Article
Journal of Health Politics, Policy and Law (1 August 2014) 39 (4): 781–809.
Published: 01 August 2014
... parent company. Civil litigation had more impact on the chain than the regulatory oversight. Copyright © 2014 by Duke University Press 2014 In recent years, there has been a growing interest in examining large nursing home chains in the United States (Kitchener et al. 2008 . The ten largest for-profit...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2014) 39 (1): 35–56.
Published: 01 February 2014
... promoted by Republican senators to deflect support for President Bill Clinton's Health Security plan. Yet the ACA was also a policy legacy of the Clinton administration in important ways that rarely are acknowledged, notably Medicaid expansion and insurance company regulation. Although the ACA departed...
Journal Article
Journal of Health Politics, Policy and Law (1 February 2015) 40 (1): 233–242.
Published: 01 February 2015
.... Thus the ability of issuers to participate across multiple public financing arrangements and to offer stable provider networks becomes crucial to achieving continuity of care. Interviews with nine companies involved in developing or operating multimarket strategies confirm the feasibility of this...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1997) 22 (2): 427–465.
Published: 01 April 1997
... companies, and private insurers. (2) Private payment distributes overall system costs according to use (or expected use) of services, costing wealthier and healthier people less than finance from (income-related) taxation. (3) Wealthy and unhealthy people can purchase (real or perceived) better access or...
Journal Article
Journal of Health Politics, Policy and Law (1 April 1997) 22 (2): 595–631.
Published: 01 April 1997
...Jonathan B. Oberlander A primary goal of many Medicare reform proposals is to move program beneficiaries into managed care plans operated by private insurance companies. Advocates contend that managed care based reforms? This article summarizes the claims that are made for and against incorporating...
Journal Article
Journal of Health Politics, Policy and Law (1 August 1986) 10 (4): 729–747.
Published: 01 August 1986
... rights applies not only to the specific situation of the baths, but also to insurance companies' aim to test all single, young, male life and health policy applicants for exposure to the putative AIDS virus; to potential health department releases of names of those testing antibody-positive for HTLV-III...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2008) 33 (6): 1031–1055.
Published: 01 December 2008
... qualitative interviews with policy makers. The first lesson for the United States is that the new Dutch health insurance model may not control costs. To date, consumer premiums are increasing, and insurance companies report large losses on the basic policies. Second, regulated competition is unlikely to make...
Journal Article
Journal of Health Politics, Policy and Law (1 December 2009) 34 (6): 979–1010.
Published: 01 December 2009
...Sandra Adamini; Hans Maarse; Esther Versluis; Donald W. Light After lengthening the duration of patents to twenty years in 1984, the pharmaceutical industry has turned to data exclusivity as a major vehicle for extending market protection, even after patents expire. Such protections give companies...